You can help expand this article with text translated from the corresponding article in Dutch. (July 2022) Click [show] for important translation instructions.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing Dutch Wikipedia article at [[:nl:Exact name of the Dutch article]]; see its history for attribution.
You may also add the template {{Translated page|nl|Exact name of Dutch article}} to the talk page.
You can help expand this article with text translated from the corresponding article in German. (March 2020) Click [show] for important translation instructions.
View a machine-translated version of the German article.
Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
Consider adding a topic to this template: there are already 1,908 articles in the main category, and specifying|topic= will aid in categorization.
Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing German Wikipedia article at [[:de:CureVac]]; see its history for attribution.
You may also add the template {{Translated|de|CureVac}} to the talk page.
At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus.[3] Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV) began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company.[3][4][5] In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy.[6] In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology.[7][8]
In 2007, Curevac received the innovation prize of the state of Baden-Württemberg[13] and was also the winner of the nationwide Weconomy competition, which is jointly awarded by the Handelsblatt newspaper and the Wissensfabrik.[14]
In March 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies.[17] Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.[18] By September 2014, the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer was to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC.[19]
In March 2015, a CureVac investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac's proprietary mRNA platform.[20] By September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac's mRNA technology.[21] That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.[22]
In accordance with its deal with Eli Lilly and Company, the company began construction on a production facility in 2016.[23]
In February 2019, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant from to develop its proprietary "RNA printer" prototype.[24] The technology is expected to allow the company to rapidly produce mRNA vaccine candidates at scale, from multiple locations globally, to bypass the logistical hurdles that often delay the production of vaccines in response to infectious disease emergencies, and also enable the production of personalized medicines.[24] The initial uses would be for their candidate vaccines for Lassa fever, yellow fever, and rabies.[24]
In July 2020, Tesla, Inc CEO Elon Musk announced via Tweet that Tesla and CureVac had reached an agreement to produce portable "RNA microfactories" based on this technology to manufacture CureVac's COVID-19 vaccine candidate.[24] CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks.[24] At approximately the same time, Tesla and CureVac filed a joint patent on the technology.[25] In August, Musk reviewed the project with Curevac while in Germany.[25]
Investment
By 2017, CureVac had received investments of approximately (€305 million) in the form of equity and was valued at €1.40 billion.[26] In June 2020, the federal government announced that the state-owned development bank KfW would immediately invest 300 million euros in CureVac, which will mean that it will hold a 23 percent stake in CureVac.[12]
On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by the company founder Ingmar Hoerr. Menichella was reported to have met U.S. President Donald Trump on 2 March.[28][29] According to Welt am Sonntag, quoting an anonymous German government source, Trump had attempted to persuade CureVac to relocate to the United States, a proposal vigorously rejected by German officials.[30] On 16 March, CureVac issued a statement on Twitter, stating "To make it clear again on coronavirus: CureVac has not received from the US government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from press."[31]
In December 2020, CureVac began a Phase III clinical trial of CVnCoV with 36,500 participants.[34][35] Bayer will provide clinical trial support and international logistics for the Phase III trial, and may be involved in eventual manufacturing should the vaccine prove to be safe and effective.[36] In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named CVnCoV (active ingredient zorecimeran), with the multinational pharmaceutical companyBayer.[36] As of December 2020, CVnCoV was in a Phase III clinical trial of 36,500.[34][35] On 12 February 2021, CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, a time-optimized process for the review of all data necessary for potential market authorization.[37]
On 16 June 2021, the CureVac announced that phase III-trials of its mRNA-vaccine showed an efficacy of 47%.[38] This falls short of the European Medicines Agency's target efficacy of at least 50%.[39]
Beyond CVnCoV, CureVac has also partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines. Human testing is due in late 2021.[40][needs update]
The start of the phase 1 study with the product candidate CV2CoV, which was announced for the fourth quarter of 2021, had to be postponed to the first quarter of 2022. Since an approval-relevant study for the new vaccine can only be carried out in the fourth quarter of 2022, the goal originally set for mid-October of “obtaining official approval for the marketability of an improved Covid-19 vaccine in 2022” can be achieved in 2023 at the earliest.[41][needs update]